Investigation & Intelligence Feeds
Leveling the Legal Playing Field: Inside Relativity’s Justice for Change Program
At Relativity Fest this year, I spoke with Johnathan Hill, Global Program Manager for Social Impact and Community Engagement Lead at Re...
AI Talks About My Quantum Articles in Three Formats: Traditional Podcast, Debating AIs and a Video Slideshow
Conceived, produced, directed and verified by Ralph Losey. Written by Google’s NotebookLM (not Losey). Click here to listen to a TRADIT...
Companies and Employees Increasingly at Risk of AI-Powered Cyber Attacks
The digital transformation has led to significant advancements in authentication and identity verification technologies and other cyber...
Akira Ransomware Continues to Hit Hard
A November 13, 2025, a Cybersecurity Advisory warned that new activity by the Akira ransomware variant “presents an imminent threat to ...
Digital Omnibus on AI Regulation – Considerations for Life Sciences Companies
The European Commission published its Digital Omnibus on AI Regulation Proposal, a legislative proposal introducing targeted measures i...
The Rising Threats of Multi-Modal and Agentic AI in Cyber Attacks
The digital transformation has led to significant advancements in authentication and identity verification technologies and other cyber...
Hogan Lovells Living Mobility Spotlight Q&A Series
What is Living Mobility? It is easier to say what it is not. The automotive and mobility industry is no longer focused on the tradition...
Behind the Scenes of Chemical Safety Reform — A Conversation with Ryan Schmit
This week I had the pleasure of speaking with Ryan N. Schmit, Of Counsel with B&C, and Senior Regulatory Consultant with The Acta G...
Federal Circuit Patent Watch: Petitioner Has No Right to Appeal “Deinstitution” of IPRs
In Re MOTOROLA SOLUTIONS, INC. (2025-134, 11/06/2025) (Dyk, Linn, Cunningham) Linn, J. The Court denied Motorola Solutions, Inc.’s ...
FDA Approves Accord BioPharma’s Denosumab Biosimilars
On November 20, 2025, the FDA approved Accord BioPharma’s denosumab biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)...